Key Takeaways
- Domestic season shifts, not lost: Sub-chronic therapies grew well, while the usual Q2 seasonal anti-infective and respiratory demand was pushed into Q3 by late rains, leaving H2 domestic growth guidance of 14%–16% intact.
- Europe revenue collapsed on a single-product destocking: One UK product, heavily overstocked during COVID, saw orders fall to "practically zero" in the quarter, an unanticipated event for both Indoco and its front-end client. Orders have now resumed.
- Margins hit by unquantified remediation spend: EBITDA margin was pressured by shorter-term costs tied to Goa Plant-II remediation and equipment layout improvements, an impact management expects for one more quarter and which was not fully understood when 17% FY24 guidance was set.
- US profit share is material but undisclosed: Management twice declined to quantify profit share from Brinzolamide and other products, citing customer confidentiality, while asserting the run rate is sustainable.
- What to watch next quarter: Whether the pushed-forward domestic season actually converts in Q3, the pace of Europe order recovery, and if remediation costs truly roll off as guided.
Domestic Business: Season Shift & Prescription Strategy
- Seasonal demand pushed forward: The usual Q2 seasonal uptick in anti-infectives, anti-cold and respiratory products did not materialize because rains arrived late, shifting that demand into Q3.
- Sub-chronic therapies delivered stability: Stomatology, ophthalmics and other sub-chronic therapies performed well in Q2, providing a stable base that helps derisk the 30%–40% topline contribution from acute products.
- Prescription heft outruns revenue rank: Indoco ranks 20th in the industry by number of prescriptions generated (above Glenmark) but only 30th in rupee terms, because acute products like Cyclopam and Febrex Plus contribute a skewed share of topline at low per-strip value.
- Mass specialist focus: The company is targeting prescriptions from mass specialists (pediatricians, ENTs, ophthalmologists, dentists, gynaecologists) rather than general practitioners, since specialists tend to prescribe acute products for longer durations by treating underlying causes.
- Anti-diabetic and pain management flat: Neither segment grew in Q2; management offered no specific reason for the anti-diabetic softness and noted pain is not a focus area for any division, with whatever pain sales exist coming through institutional channels.
Aditi Panandikar: "we are ranked 20th among in the industry when it comes to the number of prescriptions we generate. And you'd be surprised that we are couple of ranks above Glenmark as well for the absolute number of prescriptions we generate. At the same time, we are ranked 30th when it comes to our achievement in rupee terms in the market."
Europe: Single-Product Destocking Shock
- One UK product drove the decline: A product supplied to the UK was heavily overstocked during COVID and the following years, causing orders over the last three months to fall to "practically zero." The severity was unanticipated by both Indoco and its front-end client.
- Orders have resumed: Management stated orders have started being received again and visibility ahead is good, with the full-year Europe target held at ₹375–380 crores, possibly better.
Sundeep Bambolkar: "One of our products which we supply to UK got heavily overstocked during COVID and the following years. And as a result, the orders for the last 3 months have been very, very minimum, practically zero, but the situation will improve from now onwards."
Margins: Remediation Costs & the 17% Question
- Remediation costs compressed Q2 margins: Cost of goods improved and employee costs were stable or marginally lower as a percentage of sales, but other expenditure rose due to remediation costs at Goa Plant-II (which received an OAI six months ago) and equipment layout improvements that increased plant machinery repairs.
- Shorter-term, not one-off: Management described these as "shorter term" expenses, not one-off but not perennial, and expects the impact to persist for one more quarter.
- 17% EBITDA guidance under pressure: Management acknowledged that when the 17% FY24 EBITDA margin guidance was given, the remediation cost impact may not have been fully understood. The commitment is now to "try and match the 17%," with no direct yes/no on whether the ~20% H2 run rate required is achievable.
- Management declined to quantify: When asked to size the one-time increase in other expenses, management described the nature of the costs but declined to provide a number.
Aditi Panandikar: "Agreed that in the first half and probably when we made the guidance or gave the guidance, the remedial cost and their impact may not have been fully understood, but every endeavor will be done for us to try and match the 17%."
US Business: Profit Share Visible but Opaque
- Profit share is material and recurring: Management expressed confidence in sustaining the current US topline run rate and stated that Q3 and Q4 profit share from Brinzolamide and other products will be sustainable.
- No quantification provided: Twice during the call, management declined to disclose profit share numbers, citing strategic confidentiality with front-end customers.
- FDA inspection at Goa Plant I: A pre-approval inspection for two ANDAs was conducted 12th–18th October and closed with four 483s issued to the plant, an item to monitor.
Operational Initiatives & Capex
- Plant upgrades underway: Baddi Unit I received EU GMP certification in July 2023; Waluj was expanded for emerging and India market volume; Patalganga API facility added a larger QC laboratory.
- Efficiency programs: Batch size and yield improvement projects are running at multiple sites, aimed at reducing overheads, particularly human capital.
- IT roadmap: Various IT projects span HR, operations, sales and GMP-related quality assurance across manufacturing sites.
- AnaCipher CRO: A pharmacovigilance business is being contemplated in Hyderabad.
- Debt repayment schedule: ~₹24 crores in H2 FY24, then ~₹45–₹50 crores each year for the next two years.
- R&D spend: Expected at 5%–5.5% of revenue for FY24.
M&A: Scouting, Not Transacting
- Always looking, nothing available at the right price: Management is scouting for good brands in India and good facilities internationally, but stated that "neither comes cheap and neither is available."
Aditi Panandikar: "in India, we've always been scouting for good brands. And internationally, we are keen to look at good facilities, but neither comes cheap and neither is available, to be honest."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic growth | H2 must grow 14%–16% to hit full-year 11%–12% guided range; management confirmed confidence | FY24 |
| Europe revenue | ₹375–380 crores, possibly better | FY24 |
| EBITDA margin | Try to match 17% guidance; remediation cost impact not fully understood when set | FY24 |
| Remediation cost impact | Expected to persist for one more quarter | Q3 FY24 |
| US topline run rate | Confident of continuing current run rate and even better | Ongoing |
| US profit share | Q3 and Q4 profit share from Brinzolamide and other products sustainable | H2 FY24 |
| R&D spend | 5%–5.5% of revenue | FY24 |
| Debt repayment | ~₹24 crores in H2 FY24; ~₹45–₹50 crores annually for next two years | FY24–FY26 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Consolidated revenue | ₹465 cr, +15% YoY |
| Domestic formulation revenue | ₹228 cr, +9.4% YoY |
| International formulation revenue | ₹195 cr, +11.9% YoY |
| API revenue | ₹35.8 cr, +95.6% YoY |
| EBITDA | ₹72.4 cr, margin 15.6% vs 21.7% YoY |
| PAT | ₹32.9 cr, margin 7.1% vs 12% YoY |
| EPS | ₹3.60 vs ₹5.39 YoY |
| US business revenue | ₹81.4 cr, +17.5% YoY |
| Europe revenue | ₹63 cr, -15% YoY; overstocking at front-end partner impacted orders |
| Emerging markets revenue | ₹45.4 cr, +71.6% YoY |
| IPM rank and market share | 30th, 0.61% share (IQVIA Jul-Aug 23) |
| R&D spend guidance | 5%–5.5% of sales for FY24 |
| FY24 EBITDA margin guidance | 17%; H1 at 14.6%, H2 would need ~20% (per an analyst's math) |
| Europe FY24 revenue guidance | ₹375–380 cr |
| Debt repayment H2 FY24 | ~₹24 cr |